Brown & Brown Valuation
Is BRO undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
1/6Valuation Score 1/6
Unter dem Marktwert
Deutlich unter dem Marktwert
Price-To-Earnings gegen Gleichaltrige
Price-To-Earnings gegen Industrie
PM vs. Fair Ratio
Analysten-Prognose
Share Price vs Fair Value
What is the Fair Price of BRO when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Unter dem Marktwert: BRO ($74.99) wird über unserer Schätzung des Fair Value ($44.43) gehandelt.
Deutlich unter dem Marktwert: BRO über unserer Schätzung des beizulegenden Zeitwerts gehandelt wird.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for BRO?
Other financial metrics that can be useful for relative valuation.
| What is BRO's n/a Ratio? | |
|---|---|
| n/a | 0x |
| n/a | n/a |
| Market Cap | US$24.30b |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 6.6x |
| Enterprise Value/EBITDA | 20x |
| PEG Ratio | 5x |
Price to Earnings Ratio vs Peers
How does BRO's PE Ratio compare to its peers?
| Company | Forward PE | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 51.9x | ||
WTW Willis Towers Watson | 26.3x | 11.3% | US$27.7b |
RYAN Ryan Specialty Holdings | 101.6x | 50.2% | US$13.6b |
AJG Arthur J. Gallagher | 54.9x | 24.6% | US$53.3b |
AON Aon | 24.7x | 8.3% | US$63.3b |
BRO Brown & Brown | 28.3x | 5.7% | US$24.3b |
Price-To-Earnings gegen Gleichaltrige: BRO ist ein guter Wert, wenn man sein Price-To-Earnings Verhältnis (29x) mit dem Durchschnitt der anderen Unternehmen (47x) vergleicht.
Price to Earnings Ratio vs Industry
How does BRO's PE Ratio compare vs other companies in the US Insurance Industry?
Price-To-Earnings gegen Industrie: BRO ist teuer, wenn man sein Price-To-Earnings Verhältnis (29x) mit dem US Insurance Branchendurchschnitt (13.7x) vergleicht.
Price to Earnings Ratio vs Fair Ratio
What is BRO's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PE Ratio | 28.3x |
| Fair PE Ratio | 16.6x |
PM vs. Fair Ratio: BRO ist teuer auf der Grundlage des Verhältnisses Price-To-Earnings (29x) im Vergleich zum geschätzten fairen Verhältnis Price-To-Earnings (16.1x).
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
| Date | Share Price | Average 1Y Price Target | Dispersion | High | Low | 1Y Actual price | Analysts |
|---|---|---|---|---|---|---|---|
| Current | US$85.15 | US$85.83 +0.8% | 7.9% | US$98.00 | US$75.00 | n/a | 11 |
| Mar ’25 | US$83.74 | US$83.93 +0.2% | 5.7% | US$92.00 | US$75.00 | n/a | 12 |
| Feb ’25 | US$77.79 | US$84.18 +8.2% | 5.9% | US$92.00 | US$75.00 | n/a | 11 |
| Jan ’25 | US$71.11 | US$79.09 +11.2% | 5.9% | US$85.00 | US$71.00 | n/a | 11 |
| Dec ’24 | US$74.14 | US$79.60 +7.4% | 5.3% | US$85.00 | US$73.00 | n/a | 10 |
| Nov ’24 | US$69.30 | US$79.60 +14.9% | 5.3% | US$85.00 | US$73.00 | n/a | 10 |
| Oct ’24 | US$69.84 | US$78.30 +12.1% | 5.8% | US$85.00 | US$70.00 | n/a | 10 |
| Sep ’24 | US$74.20 | US$78.10 +5.3% | 5.6% | US$85.00 | US$70.00 | n/a | 10 |
| Aug ’24 | US$70.00 | US$76.40 +9.1% | 6.2% | US$85.00 | US$70.00 | n/a | 10 |
| Jul ’24 | US$68.84 | US$69.20 +0.5% | 5.0% | US$73.00 | US$62.00 | n/a | 10 |
| Jun ’24 | US$62.75 | US$69.20 +10.3% | 5.0% | US$73.00 | US$62.00 | n/a | 10 |
| May ’24 | US$65.83 | US$68.70 +4.4% | 4.9% | US$73.00 | US$62.00 | n/a | 10 |
| Apr ’24 | US$57.42 | US$65.10 +13.4% | 5.6% | US$70.00 | US$59.00 | US$86.32 | 10 |
| Mar ’24 | US$56.01 | US$65.10 +16.2% | 5.6% | US$70.00 | US$59.00 | US$83.74 | 10 |
| Feb ’24 | US$58.40 | US$65.10 +11.5% | 5.6% | US$70.00 | US$59.00 | US$77.79 | 10 |
| Jan ’24 | US$56.97 | US$65.22 +14.5% | 6.3% | US$72.00 | US$60.00 | US$71.11 | 9 |
| Dec ’23 | US$58.92 | US$65.56 +11.3% | 6.0% | US$72.00 | US$60.00 | US$74.14 | 9 |
| Nov ’23 | US$58.65 | US$66.00 +12.5% | 6.2% | US$72.00 | US$60.00 | US$69.30 | 9 |
| Oct ’23 | US$60.48 | US$70.33 +16.3% | 4.6% | US$75.00 | US$66.00 | US$69.84 | 9 |
| Sep ’23 | US$63.66 | US$70.33 +10.5% | 4.6% | US$75.00 | US$66.00 | US$74.20 | 9 |
| Aug ’23 | US$63.18 | US$70.22 +11.1% | 6.0% | US$76.00 | US$64.00 | US$70.00 | 9 |
| Jul ’23 | US$59.33 | US$74.63 +25.8% | 7.7% | US$82.00 | US$64.00 | US$68.84 | 8 |
| Jun ’23 | US$58.01 | US$72.89 +25.6% | 10.0% | US$82.00 | US$59.00 | US$62.75 | 9 |
| May ’23 | US$61.98 | US$74.56 +20.3% | 6.6% | US$82.00 | US$68.00 | US$65.83 | 9 |
| Apr ’23 | US$72.56 | US$71.50 -1.5% | 7.3% | US$79.00 | US$65.00 | US$57.42 | 8 |
Analysten-Prognose: Das Kursziel liegt weniger als 20% über dem aktuellen Aktienkurs.